SAN DIEGO — A single dose of a dihydroergotamine mesylate (DHE) nasal powder formulation appears to quickly and significantly reduce migraine pain, results of a new phase 3 study showed. DHE is an ...
Credit: Shutterstock. A regulatory decision is expected in January 2024. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for STS101 (dihydroergotamine ...
The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for STS101 (dihydroergotamine [DHE] nasal powder) for the acute treatment of migraine with or ...
The recommended dose of Atzumi is 5.2 mg, the contents of 1 nasal device, administered into 1 nostril. The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for ...
AUSTIN, Texas — Sustained freedom from pain and the most bothersome migraine symptom was achieved in more patients treated with investigational STS 101 compared with placebo, according to a study ...
The FDA approved dihydroergotamine (DHE) nasal powder (Atzumi) 5.2 mg to treat acute migraine with or without aura in adults, Satsuma Pharmaceuticals announced Wednesday. The product is the only DHE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback